Request Demo

Last update 08 May 2025

AGRE2

Last update 08 May 2025

Basic Info

Synonyms

ADGRE2, adhesion G protein-coupled receptor E2, CD312

+ [5]

Introduction

Cell surface receptor that binds to the chondroitin sulfate moiety of glycosaminoglycan chains and promotes cell attachment. Promotes granulocyte chemotaxis, degranulation and adhesion. In macrophages, promotes the release of inflammatory cytokines, including IL8 and TNF. Signals probably through G-proteins. Is a regulator of mast cell degranulation (PubMed:26841242).

Drugs associated with AGRE2

ADCLEC.syn1 CAR T cells(Takeda)

Target

AGRE2 x CLL-1

Mechanism

AGRE2 inhibitors [+3]

Active Org.

Takeda Pharmaceutical Co., Ltd.

Originator Org.

Takeda Pharmaceutical Co., Ltd.

Active Indication

Relapsing acute myeloid leukemia

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Anti-ADGRE2 CAR-T (Zhejiang University)

Target

AGRE2

Mechanism

AGRE2 inhibitors

Active Org.

Zhejiang University

Originator Org.

Zhejiang University

Active Indication

Acute Myeloid Leukemia

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

EMR2-targeted CAR-T (Vor BioPharma)

Target

AGRE2

Mechanism

AGRE2 inhibitors

Active Org.

Vor Biopharma, Inc.

Originator Org.

Vor Biopharma, Inc.

Active Indication

Acute Myeloid Leukemia

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with AGRE2

NCT05748197

/ RecruitingPhase 1IIT

A Phase I Study of ADCLEC.syn1 CAR T Cells in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia

The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this dose, it will test it in a new group of participants to see if it is effective in treating their relapsed/refractory AML.

Start Date18 Apr 2024

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

[+1]

NCT05463640

/ Not yet recruitingPhase 1IIT

To Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With Relapsed and Refractory Acute Myeloid Leukemia

This is an open label, phase I study to assess the safety and efficacy of ADGRE2 CAR-T in patients with relapsed and refractory acute myeloid leukemia

Start Date02 Aug 2022

Sponsor / Collaborator

Zhejiang University

ChiCTR2200061646

/ SuspendedEarly Phase 1

To evaluate the safety and efficacy of CLL1/CLL1+CD33/CD33/ADGRE2 CAR-T in the treatment of relapsed and refractory acute myeloid leukemia

Start Date16 Jun 2022

Sponsor / Collaborator

Guangzhou Bio-gene Technology Co., Ltd.

100 Clinical Results associated with AGRE2

100 Translational Medicine associated with AGRE2

0 Patents (Medical) associated with AGRE2

Literatures (Medical) associated with AGRE2

16 Mar 2025·Postgraduate Medical Journal

Therapeutic targets for gastrointestinal diseases: proteome-wide Mendelian randomization and colocalization analyses

Article

Author: Yang, Zhihao ; Pan, Jun ; Zhan, Daqin ; Li, Pengcheng

AbstractPurposeThis study was aimed to identify serum proteins linked with gastrointestinal diseases by proteome-wide Mendelian randomization analysis.MethodsWe determined the casual relationship between 732 kinds of circulating proteins and the 24 kinds of gastrointestinal diseases via Mendelian randomization analysis.ResultsFour circulating proteins (FCGR3B, IL-12B, MAPKAPK2, and IL-23R) were associated with the occurrence of ulcerative colitis (UC), and IL23R was also correlated with risk of Crohn's disease (CD). Genetically predicted levels of IL23R were strongly correlated with the risk of UC and CD based on the high supporting evidence of colocalization analysis. Five circulating proteins (NOV, EFEMP1, ADGRE2, LCT, and SEMA3G) were associated with the risk of diverticulosis disease. With high supporting evidence of colocalization, genetically predicted levels of NOV and SEMA3G were inversely correlated with the risk of diverticulosis disease. Five circulating proteins (FUT3, FUT5, CRHBP, SULT2A1, and QPCTL) were associated with the occurrence of cholelithiasis. With high supporting evidence of colocalization, genetically predicted levels of FUT3 and CRHBP were inversely correlated with the risk of cholelithiasis.ConclusionsThe proteome-wide Mendelian randomization investigation identified several circulating proteins associated with the risk of UC, CD, diverticular disease and cholelithiasis, which reinforced the understanding of molecular pathogenesis and design of therapeutic targets.

01 Feb 2025·Rheumatology

Associations between plasma metabolism-associated proteins and future development of giant cell arteritis: results from a prospective study

Article

Author: Turesson, Carl ; Wadström, Karin ; Jakobsson, Magnus E ; Warrington, Kenneth J ; Mohammad, Aladdin J ; Matteson, Eric L ; Jacobsson, Lennart T H

AbstractObjectiveThe aim of this study was to investigate the relationship between biomarkers associated with metabolism and subsequent development of GCA.MethodParticipants in the population-based Malmö Diet Cancer Study (MDCS; N = 30 447) who were subsequently diagnosed with GCA were identified in a structured process. Matched GCA-free controls were selected from the study cohort. Baseline plasma samples were analysed using the antibody-based OLINK proteomics metabolism panel (92 metabolic proteins). Analyses were pre-designated as hypothesis-driven or hypothesis-generating. In the latter, principal component analysis was used to identify groups of proteins that explained the variance in the proteome.ResultsThere were 95 cases with a confirmed incident diagnosis of GCA (median 12.0 years after inclusion). Among biomarkers with a priori hypotheses, adhesion G protein-coupled receptor E2 (ADGRE2) was positively associated [odds ratio (OR) per S.D. 1.67; 95% CI 1.08–2.57], and fructose-1,6-bisphosphatase 1 (FBP1) was negatively associated (OR per S.D. 0.59; 95% CI 0.35–0.99) with GCA. In particular, ADGRE2 levels were associated with subsequent GCA in the subset sampled <8.5 years before diagnosis. For meteorin-like protein (Metrnl), the highest impact on the risk of GCA was observed in those patients sampled closest to diagnosis, with a decreasing trend with longer time to GCA (P = 0.03). In the hypothesis-generating analyses, elevated levels of receptor tyrosine-like orphan receptor 1 (ROR1) were associated with subsequent GCA.ConclusionBiomarkers identified years before clinical diagnosis indicated a protective role of gluconeogenesis (FBP1) and an association with macrophage activation (ADGRE2 and Metrnl) and proinflammatory signals (ROR1) for development of GCA.

01 Feb 2025·International Journal of Laboratory Hematology

Application of Gene Expression Microarray for the Classification of Ph‐Like B‐Cell Acute Lymphoblastic Leukemia

Article

Author: Pakakasama, Samart ; Pongphitcha, Pongpak ; Chareonsirisuthigul, Takol ; Thangrua, Nonthaya ; Mukda, Ekchol ; Chutipongtanate, Somchai ; Siriboonpiputtana, Teerapong ; Rerkamnuaychoke, Budsaba ; Korkiatsakul, Veerawat

ABSTRACTIntroductionPh‐like ALL has gene expression profile similar to Ph‐positive ALL but without the BCR::ABL1 fusion. The disease presents higher rates of severe clinical features and is associated with unfavorable outcomes. There is still no standard pipeline for molecular characterization of the disease, and no valid predictor gene panel is available worldwide.MethodsWe performed expression microarray on 25 B‐cell ALL and 6 Ph‐positive B‐cell ALL to cluster and identify the transcriptional signature of Ph‐like ALL. qRT‐PCR was used to confirm the expression of candidate genes.ResultsFour out of 25 samples (16%) shared gene expression signatures related to and clustered with control Ph‐positive samples. Analysis of genes differentially expressed in Ph‐like B‐cell ALL and evidentially functional in normal blood cell development and leukemogenesis, we selected genes as potential biomarkers for Ph‐like B‐cell ALL in our dataset: ADGRE2, CD9, EPHA7, FAM129C, TCL1A, and VPREB1. Those genes were filtered by Ph‐like gene signatures obtained from distinct reliable data, resulting in five genes, CA6, CHN2, JAK1, JCHAIN, and PON2, selected for validation by qRT‐PCR. The Ct values of genes, including CA6 (p = 0.0017), PON2 (p = 0.0210), TCL1A (p = 0.0064), and VPREB1 (p = 0.0338), were significant in Ph‐like ALL. GSEA analysis identified VPREB1 as enrichment in the KRAS signaling pathway, and several genes that interact with VPREB1 were reported as critical molecules involved in the leukemogenesis of B‐cell ALL.ConclusionIn summary, we demonstrate using a gene expression microarray for classifying Ph‐like B‐cell ALL and highlight VPREB1 as a potential biomarker for this disease.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

AGRE2

Basic Info

Related

Analysis